Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Divestiture Possible For Merck’s Animal Health, Consumer Units; Januvia’s Sales Slide

This article was originally published in The Pink Sheet Daily

Executive Summary

The performance of Merck’s diabetes franchise came under scrutiny by analysts on an earnings call Oct 28, after the company reported sales of its number one drug fell 5% in the third quarter year on year. Top executives came closer than ever to saying they are inclined to divest non-core businesses, including animal health.


Related Content

“Likely” Merck Consumer-Health Sale Could Bring $8 Billion – Analysts
Emerging Markets Earnings Roundup: Pfizer, Merck, AbbVie (Part 4)
Merck And Pfizer Make A Late Play For The Diabetes Market


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts